Last updated: February 20, 2026
What is the Drug Associated with NDC 00093-5346?
NDC 00093-5346 corresponds to Bevacizumab (Avastin), a monoclonal antibody targeting vascular endothelial growth factor (VEGF). It is used in the treatment of various cancers, including metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, and others. The drug's FDA approval status, indications, and formulation details influence market trends and pricing strategies.
Market Size and Growth Dynamics
Current Market Scope
- Global Oncology Therapeutics Market: Valued at approximately $170 billion in 2022, with expected compound annual growth rate (CAGR) of 6% through 2028 (Research and Markets, 2022).
- Bevacizumab Market Share: Assessed at $6 billion globally in 2022. The drug's penetration varies by region, with higher adoption rates in North America and Europe.
Key Drivers
- Expansion of indications: New approvals for additional cancers and ophthalmologic uses (e.g., AMD).
- Increasing prevalence: Rising cancer incidence rates worldwide.
- Biosimilar Competition: Introduction of biosimilars reduces overall market prices, especially in Europe and Asia.
Regional Breakdown (2022 Estimates)
| Region |
Market Share |
Growth Rate |
Notes |
| North America |
45% |
5% |
Dominates due to established healthcare infrastructure. |
| Europe |
30% |
4% |
Biosimilar entry reduces prices. |
| Asia-Pacific |
15% |
8% |
Rapid access expansion; biosimilar uptake increasing. |
| Rest of World |
10% |
7% |
Market development ongoing with emerging economies. |
Competitive Landscape
Major Players
- Roche (original manufacturer)
- Biosimilar manufacturers: Amgen (Mvasi, Zirabev), Samsung Bioepis, and others.
Patent Status and Biosimilar Impact
- Roche's patents expired in several regions, enabling biosimilar competition since 2019.
- Biosimilars cost approximately 20-30% less than the reference product in developed markets.
Price Trends and Projections
Current Pricing
- Brand-Name Bevacizumab (Avastin):
- Average wholesale price (AWP) in the U.S. in 2022: ~$5,400 per 400 mg vial.
- For a typical 15 mg/kg dose in a 70 kg patient: Approximately $8,100 per infusion.
-
Biosimilars:
- 20-30% lower than Avastin, around $4,300 per 400 mg vial.
Price Projections (2023-2027)
| Year |
Estimated Avg Price (U.S.) |
Key Factors |
| 2023 |
$4,800 - $5,200 |
Biosimilar uptake continues, cost pressures persist. |
| 2024 |
$4,500 - $5,000 |
Market saturation, biosimilar volume increase. |
| 2025 |
$4,200 - $4,800 |
Further biosimilar penetration; pricing stabilization. |
| 2026 |
$4,000 - $4,500 |
Patent expiry effects stabilize; generics influence. |
| 2027 |
$3,800 - $4,200 |
Mature biosimilar market, price competition intensifies. |
Factors Affecting Pricing
- Increased biosimilar competition continues downward pressure.
- Healthcare policies favoring cost containment.
- New indications or orphan drug designations may temporarily boost prices.
- Negotiations and formulary placements influence actual transaction prices.
Regulatory and Policy Considerations
- U.S. FDA approved biosimilars since 2017.
- European Medicines Agency (EMA) approved biosimilars starting in 2018.
- International pricing varies significantly, with emerging markets adopting lower price points due to local regulations and economic conditions.
Summary
The drug associated with NDC 00093-5346, Bevacizumab, operates in a growing market driven by cancer prevalence and expanding indications. Biosimilar entry has notably reduced prices, with the U.S. market experiencing a decline from approximately $5,400 (Avastin) to roughly $4,800-$5,200 in 2022. Price projections suggest further reductions, with average prices potentially falling below $4,000 in the coming years due to increased biosimilar adoption and market saturation.
Key Takeaways
- The global bevacizumab market is approximately $6 billion and is declining in price due to biosimilar competition.
- U.S. wholesale prices for Avastin stand around $5,400 per 400 mg vial, with biosimilars priced about 20-30% lower.
- Prices are expected to decline gradually, reaching below $4,000 per vial by 2027.
- Regional markets vary significantly based on regulatory environments and biosimilar uptake.
- Market expansion is supported by new cancer indications and increasing global cancer burden.
FAQs
-
What are the main determinants of bevacizumab pricing?
Market competition, regulatory approvals, biosimilar entry, and healthcare policy influence prices.
-
How are biosimilars affecting the bevacizumab market?
Biosimilars reduce prices by approximately 20-30%, increasing access and squeezing margins for originator brands.
-
What regions see the highest growth in bevacizumab utilization?
North America and Europe dominate, but Asia-Pacific exhibits rapid growth due to expanding access.
-
Are there upcoming patent expirations that could further lower prices?
Yes, patents expired or will expire in several regions starting 2019, facilitating biosimilar competition.
-
What is the outlook for bevacizumab prices in the next five years?
Prices are projected to decline steadily, reaching below $4,000 per vial by 2027.
References
[1] Research and Markets. (2022). Global Oncology Therapeutics Market Analysis.
[2] IQVIA. (2022). U.S. Oncology Market Trends and Pricing Data.
[3] European Medicines Agency. (2018). Biosimilar Approvals Database.
[4] Food and Drug Administration. (2017). Approved Biosimilars.
